CA2303424A1 - Kay, nouvelle proteine du systeme immunitaire - Google Patents

Kay, nouvelle proteine du systeme immunitaire Download PDF

Info

Publication number
CA2303424A1
CA2303424A1 CA002303424A CA2303424A CA2303424A1 CA 2303424 A1 CA2303424 A1 CA 2303424A1 CA 002303424 A CA002303424 A CA 002303424A CA 2303424 A CA2303424 A CA 2303424A CA 2303424 A1 CA2303424 A1 CA 2303424A1
Authority
CA
Canada
Prior art keywords
ligand
kay
seq
dna
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303424A
Other languages
English (en)
Inventor
Jurg Tschopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APOTECH R&D SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303424A1 publication Critical patent/CA2303424A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à Kay, nouveau membre de la famille des facteurs de nécrose des tumeurs (TNF), à des ligands Kay modifiés et à des compositions pharmaceutiques qui les renferment.
CA002303424A 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire Abandoned CA2303424A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12
PCT/US1998/019037 WO1999012964A2 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire

Publications (1)

Publication Number Publication Date
CA2303424A1 true CA2303424A1 (fr) 1999-03-18

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303424A Abandoned CA2303424A1 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire

Country Status (17)

Country Link
EP (1) EP1012270A2 (fr)
JP (1) JP2001515711A (fr)
KR (1) KR20010023892A (fr)
CN (1) CN1269832A (fr)
AU (1) AU9315298A (fr)
BR (1) BR9812433A (fr)
CA (1) CA2303424A1 (fr)
EA (1) EA200000311A1 (fr)
EE (1) EE200000148A (fr)
HU (1) HUP0004034A3 (fr)
IL (1) IL134480A0 (fr)
IS (1) IS5375A (fr)
NO (1) NO20001240L (fr)
PL (1) PL339740A1 (fr)
SK (1) SK3532000A3 (fr)
TR (1) TR200000654T2 (fr)
WO (1) WO1999012964A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (fr) * 1997-11-26 1999-06-03 Eli Lilly And Company Gene de la famille des ligands du tnf
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
WO2001060397A1 (fr) 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CZ299819B6 (cs) 1999-01-25 2008-12-03 Biogen Idec Ma Inc. Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1860190A3 (fr) * 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (fr) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Molecules d'acide nucleique, proteines et recepteurs tall-1, et procedes d'utilisation
HK1043608B (en) * 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1259544B1 (fr) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Polypeptide heterologue de la famille tnf
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1309718A4 (fr) * 2000-08-15 2004-08-25 Human Genome Sciences Inc Neutrokine-alpha et variant d'epissage de neutrokine-alpha
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP1608730B1 (fr) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Recepteurs baff tronques
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
WO2005042009A1 (fr) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Regimes therapeutiques pour antagonistes baff
WO2005075511A1 (fr) * 2004-01-29 2005-08-18 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
CN101087807A (zh) 2004-10-05 2007-12-12 健泰科生物技术公司 治疗血管炎的方法
NZ583905A (en) 2004-10-13 2011-12-22 Univ Washington Use of BAFF to Treat Sepsis
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
WO2007134326A2 (fr) 2006-05-15 2007-11-22 Ares Trading S.A. Procédés de traitement des maladies auto-immunes à l'aide d'une molécule de fusion taci-ig
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック, インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
JP6577958B2 (ja) 2014-04-11 2019-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ[3H−インドール−3,2’−ピロリジン]−2(1H)−オン誘導体およびMDM2−p53阻害剤としてのそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
WO1996040774A1 (fr) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques
NZ334309A (en) * 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf

Also Published As

Publication number Publication date
HUP0004034A3 (en) 2002-08-28
JP2001515711A (ja) 2001-09-25
EP1012270A2 (fr) 2000-06-28
CN1269832A (zh) 2000-10-11
NO20001240L (no) 2000-05-10
BR9812433A (pt) 2000-09-26
EA200000311A1 (ru) 2000-10-30
NO20001240D0 (no) 2000-03-09
TR200000654T2 (tr) 2000-07-21
AU9315298A (en) 1999-03-29
WO1999012964A3 (fr) 1999-05-27
EE200000148A (et) 2001-02-15
KR20010023892A (ko) 2001-03-26
PL339740A1 (en) 2001-01-02
HUP0004034A2 (en) 2001-03-28
IS5375A (is) 2000-02-11
WO1999012964A2 (fr) 1999-03-18
SK3532000A3 (en) 2001-12-03
IL134480A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AU9315298A (en) Kay - a novel immune system protein
AU759717B2 (en) April- a novel protein with growth effects
EP0956351B1 (fr) Ligand associe a un facteur de necrose tumorale
US7087725B2 (en) Antibodies specifically reactive with a tumor necrosis factor related ligand
AU774498B2 (en) A tumor necrosis factor related ligand
HK1025994B (en) A tumor necrosis factor related ligand
CZ2000867A3 (cs) Sekvence DNA kódující ligand Kay, způsob přípravy ligandu Kay a farmaceutický přípravek obsahující tento ligand
MXPA99001342A (en) A tumor necrosis factor related ligand
AU2003213481A1 (en) APRIL - A Novel Protein With Growth Effects

Legal Events

Date Code Title Description
FZDE Discontinued